GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: PRAX-222 | PRAX222
Compound class:
Nucleic acid
Comment: Elsunersen (PRAX-222) is a 20-mer anti-sense oligonucleotide that is designed to selectively decrease expression of the gene for the voltage-gated sodium channel Nav1.2 (SCN2A). This is proposed as a mechanism to treat early onset developmental and epileptic encephalopathy (DEE) [1-3], that is driven by gain-of-function mutations in SCN2A. We include the linear nucleotide sequence in this entry, without the chemical modifications that are included in the administered version of elsunersen. A full descriptor is d([2'-O-(2-methoxyethyl)](m5rC-sp-m5rC-rA-5rC-rG-rA)-5C-sp-A-sp-T-p-A-p-T-p-T-p-T-p-T-p-T-p-m5C-sp-[2'-O-(2-methoxyethyl)]m5rU-[2'-O-(2-methoxyethyl)]rA-sp-[2'-O-(2-methoxyethyl)]m5rC-sp-[2'-O-(2-methoxyethyl)]rA).
|
Classification ![]() |
|
Compound class | Nucleic acid |
Compound subclass | Antisense oligonucleotide (ASO) |
Target | SCN2A mRNA |
International Nonproprietary Names ![]() |
|
INN number | INN |
12610 | elsunersen |
Synonyms ![]() |
PRAX-222 | PRAX222 |
Database Links ![]() |
|
CAS Registry No. | 2756001-75-7 (source: WHO INN record) |
Search PubMed clinical trials | elsunersen |
Search PubMed titles | elsunersen |
Search PubMed titles/abstracts | elsunersen |